A highly annotated profile of 90 AJCC Stage ll colon cancers undergoing curative surgery between 1997 and 2006 at the Academic Medical Centre (AMC), The Netherlands, were included as the validation cohort (AMC-AJCCII-90) [31]. Similar to the discovery set, a ranked list of differentially expressed genes between high (>15) and low (≤15) LN yield samples were generated (GSE33113) using GEO2R and tested against the ‘hallmark’ gene sets, immune signatures and xCell type signatures for enrichment [32].
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.